Alyeska Investment Group
BNTC icon

Alyeska Investment Group’s Benitec Biopharma BNTC Stock Holding History

Alyeska Investment Group’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10M Hold
750,000
– – 0.03% 428
2026
Q1 		$7.99M Hold
750,000
– – 0.02% 426
2025
Q4 		$10.1M Buy
+750,000
New +$10.4M 0.03% 387

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Alyeska Investment Group's BNTC Position: Q2 2026 in Review

Alyeska Investment Group held its Benitec Biopharma (BNTC) position steady in Q2 2026 at 750,000 shares worth $10M. The position accounts for 0.03% of the portfolio, ranked #428.

Alyeska Investment Group first reported a position in BNTC in Q4 2025 and has held it in 3 quarters since. The position peaked at $10.1M in Q4 2025. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Alyeska Investment Group held 750,000 shares of Benitec Biopharma worth $10M as of Q2 2026.
  • Alyeska Investment Group left its Benitec Biopharma share count unchanged in Q2 2026.
  • Benitec Biopharma made up 0.03% of Alyeska Investment Group's portfolio in Q2 2026, its #428 holding.
  • Alyeska Investment Group first reported a position in Benitec Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Alyeska Investment Group's Benitec Biopharma position peaked at $10.1M in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.